FDA to Athersys: Design of large stem cell trial looks good – Crain’s Cleveland Business
|
FDA to Athersys: Design of large stem cell trial looks good
Crain’s Cleveland Business Federal regulators have told Athersys Inc. that the design of its planned Phase 3 clinical trial looks good. So if stoke patients in the trial respond well to Athersys' adult stem cell therapy, the company should be able to apply for the right to begin … Athersys Receives FDA Agreement Under Special Protocol Assessment for Phase 3 Study of MultiStem® Treatment for … |
